---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-048998"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T06:36:35.339703+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares

## Summary
- Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.
- Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000 shares.
- Election of Class I directors Michael Byrnes and Lindsey Rolfe, M.D. to serve until 2028 annual meeting.
- Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year 2025.
- Also approved issuance of shares upon exercise of February 2025 warrants and conversion of Series D preferred below market price.

## SEC filing metadata
- accession: 0001213900-25-048998
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025048998/0001213900-25-048998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025048998/ea0243837-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-048998
- JSON: https://secwatch.observer/filing/0001213900-25-048998.json
- Plain text: https://secwatch.observer/filing/0001213900-25-048998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.